Ocular Therapeutix Inc (NASDAQ:OCUL) Director Richard L. Md Lindstrom purchased 56,441 shares of the firm’s stock in a transaction on Wednesday, March 13th. The stock was acquired at an average cost of $4.33 per share, with a total value of $244,389.53. Following the transaction, the director now directly owns 100,000 shares in the company, valued at $433,000. The purchase was disclosed in a filing with the SEC, which is available at this link.
Shares of OCUL traded down $0.04 during midday trading on Friday, reaching $4.05. The stock had a trading volume of 731,216 shares, compared to its average volume of 495,230. Ocular Therapeutix Inc has a 1-year low of $3.46 and a 1-year high of $8.28. The firm has a market capitalization of $178.20 million, a price-to-earnings ratio of -2.58 and a beta of 1.89. The company has a current ratio of 6.14, a quick ratio of 6.11 and a debt-to-equity ratio of 0.69.
Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.05). Ocular Therapeutix had a negative net margin of 3,013.97% and a negative return on equity of 136.09%. The firm had revenue of $0.50 million during the quarter, compared to analyst estimates of $0.45 million. On average, analysts predict that Ocular Therapeutix Inc will post -1.47 earnings per share for the current fiscal year.
Several equities analysts have commented on OCUL shares. Cantor Fitzgerald raised their price target on shares of Ocular Therapeutix from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Monday, December 3rd. HC Wainwright set a $12.00 price target on shares of Ocular Therapeutix and gave the company a “buy” rating in a research report on Friday, January 11th. BidaskClub upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Sunday, December 2nd. Cowen restated a “buy” rating and issued a $13.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, December 4th. Finally, ValuEngine upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $12.61.
COPYRIGHT VIOLATION WARNING: This story was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/4224437/ocular-therapeutix-inc-ocul-director-richard-l-md-lindstrom-purchases-56441-shares.html.
About Ocular Therapeutix
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.